Reporting rate of Guillain-Barr\u00e9 syndrome higher compared with other vaccinations, but rate within incidence range for general population<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
<\/strong>MONDAY, Oct. 17, 2022 (HealthDay News) — There is an increase in the reporting rate of Guillain-Barr \u00a9 syndrome (GBS) after COVID-19 vaccination, but the rate is within the incidence range for the general population, according to a study published online Sept. 22 in Vaccine<\/em>.<\/p>\n Mustafa Jaffry, from Rutgers New Jersey Medical School in Newark, and colleagues compared the reporting rate of adult GBS after COVID-19 vaccination to the reporting rate after other vaccinations during the same time period and during control time periods.<\/p>\n The researchers observed a significantly higher reporting rate of GBS after COVID-19 vaccination than after influenza and other vaccinations (49.7, 0.19, and 0.16 per 10 million, respectively). The reporting rate for GBS was within the general population incidence range. A significant difference in the reporting rate of GBS after COVID-19 vaccination was seen between the risk period and control period using self-controlled and case-centered analyses. Within six weeks of COVID-19 vaccination, there were an estimated 0.7 to 1.7 per million excess reports of GBS. Associations for worse outcome were seen for female gender and age 18 to 44 years in a machine learning model. There was no association between the onset interval of GBS and prognosis.<\/p>\n “This study seeks to add to the body of knowledge surrounding the association between COVID-19 vaccination and GBS, so that health care providers may explain the risk\/benefit ratio to patients to aid adherence to vaccination guidelines,” the authors write.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n